Form 4: PTGX Director Waddill Granted Equity

Protagonist Therapeutics director William D. Waddill was granted 2,695 restricted stock units and options for 3,762 shares of common stock.

Summary

• William D. Waddill, a director of Protagonist Therapeutics, Inc. (PTGX), received an equity grant on January 2, 2026.
• The grant includes 2,695 shares of common stock in the form of restricted stock units (RSUs).
• These RSUs will vest in full on January 15, 2027, contingent on Mr. Waddill's continued service to the Issuer.
• Additionally, Mr. Waddill was granted stock options for 3,762 shares of common stock.
• The stock options have an exercise price of $87.18 per share and an expiration date of January 2, 2036.
• The options will vest in 12 equal monthly installments following January 2, 2026, also subject to continued service.
• Following these transactions, Mr. Waddill beneficially owns 7,825 shares of common stock and 3,762 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of equity to a director is a positive for aligning interests and retention, though it's a routine compensation event rather than a significant operational or financial development.

Positives

• The equity grant aligns the director's interests with those of shareholders, promoting long-term commitment to Protagonist Therapeutics.
• It serves as a retention incentive for William D. Waddill, a director, contributing to stability in corporate governance.

Negatives

• The issuance of new equity, even for compensation, can lead to minor dilution for existing shareholders over time as shares vest and options are exercised.

Risks

• The value of the granted restricted stock units and stock options is subject to the future market price fluctuations of Protagonist Therapeutics' common stock.
• Vesting of both the RSUs and stock options is contingent upon William D. Waddill's continued service to the Issuer through the respective vesting dates, meaning the full benefit is not guaranteed if service ceases.

Future Outlook

The equity grants with multi-year vesting schedules indicate an expectation of continued service from William D. Waddill as a director, suggesting stability in corporate governance and long-term commitment.

Industry Context

Equity grants to directors and executives are a standard practice in the biotechnology and pharmaceutical industries, aligning management incentives with long-term shareholder value creation. This filing reflects a routine compensation event consistent with industry norms.

Comparison to Industry Standards

• Equity compensation, including restricted stock units and stock options, is a common practice across publicly traded companies, particularly in high-growth sectors like biotechnology.
• The structure of vesting over time is standard for retention and performance alignment, consistent with general industry benchmarks for director compensation.

Related Party Transactions

• Grant of 2,695 restricted stock units to William D. Waddill, a director of Protagonist Therapeutics, Inc.
• Grant of stock options for 3,762 shares to William D. Waddill, a director of Protagonist Therapeutics, Inc.

Stakeholder Impact

• Shareholders: Potential minor dilution from the issuance of new shares upon vesting/exercise, but also benefit from aligned director incentives.
• Director (William D. Waddill): Receives significant equity compensation, aligning personal financial interests with company performance and providing a retention incentive.

Next Steps

• Vesting of 2,695 restricted stock units on January 15, 2027.
• Monthly vesting of 3,762 stock options following January 2, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a director, which is a standard compensation practice. It does not contain information that would fundamentally alter the company's financial outlook, operational performance, or strategic direction. Therefore, it does not warrant a change in an investor's existing position, leading to a 'hold' recommendation.

Keywords

Protagonist Therapeutics, PTGX, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, Director Compensation, Beneficial Ownership